DAVENPORT & Co LLC reduced its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 3.3% in the fourth quarter, ...

Novartis AG (NVS) stock saw a modest uptick, ending the day at $105.48 which represents a slight increase of $0.76 or 0.73% from the prior close of $104.72. The stock opened at $104.47 and touched a ...

Chicago Partners Investment Group LLC bought a new stake in shares of Novartis AG (NYSE:NVS – Free Report) during the 4th ...

The Delhi High Court on February 3 passed an interim injunction restraining a pharmaceutical company from using the trademark ...

As the global markets navigate a complex landscape marked by volatile tech stocks, geopolitical tariff tensions, and shifting ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

The global nucleic acid testing market is witnessing unprecedented growth, with a market size of USD 3.7 billion in 2023, driven by a robust compound annual growth rate (CAGR) of 6.8%. By the end of ...

Additionally, as the Sandoz spin-off was completed on October 2023, there were no operating results in 2024 related to discontinued operations.

Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell.

Cambridge biotech company Astex belatedly celebrated its 25th anniversary in style with UK Science Minister and new trade ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...